Infection Medications: Assessment In-Vitro Glutathione S-Transferase Inhibition and Molecular Docking Study

ArticleAçık Erişim

Özet

Glutathione S-transferases (EC 2.5.1.18, GSTs), consisting of at least seven subfamilies, such as alpha, kappa, mu, pi, theta, zeta, and omega, are the family of cytosolic proteins with many known functions and also are abundant in cells. Moreover, they play significant roles in influencing the efficacy and bioavailability of pharmaceutical agents in humans. It is also known that multiple types of cancer tissue frequently have high levels of GSTs compared to the corresponding healthy tissue. Herein, firstly, the GST was purified from human erythrocytes by rapid and straightforward chromatographic techniques. Subsequently, the active infection medications, the antimycotics (amphotericin B, anidulafungin, and caspofungin), antibacterials (daptomycin, ertapenem, and tigecycline), and antiviral (ganciclovir) were assessed for their inhibitory actions versus GST. All drugs demonstrated micromolar levels of potent inhibitory activity towards GST. Antifungal drugs had KI constants ranging between 20.60±0.05 μM and 50.43±0.12 μM, whilst antibacterial drugs exhibited KIs in the range of 20.92±0.09–114.80±0.41 μM. Daptomycin and ertapenem exhibited competitive inhibition, while other drugs in noncompetitive inhibition. Moreover, amphotericin B exhibited the most potent inhibitory activity (KI=20.60±0.05 μM), and in contrast, antiviral drug ganciclovir had the highest inhibition constant (KI=463.10±1.28 μM). Studying both in-vitro inhibitory activity and molecular docking interactions in silico activities of these infection medications in complex with the GST, an enzyme biologically important, demonstrates was caused significant associations between these drugs and GST were detected. The results here might provide structural guidance to design more potent GST inhibitors. © 2021 Wiley-VCH GmbH

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/13372Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1002/slct.202103197Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorTürkeş, Cüneyt
dc.contributor.authorDemir, Yeliz
dc.contributor.authorBeydemir, Şükrü
dc.date.accessioned2026-10-18T20:28:12.731564697Z
dc.date.available2026-10-18T20:28:12.731564697Z
dc.date.issued2021
dc.description.abstractGlutathione S-transferases (EC 2.5.1.18, GSTs), consisting of at least seven subfamilies, such as alpha, kappa, mu, pi, theta, zeta, and omega, are the family of cytosolic proteins with many known functions and also are abundant in cells. Moreover, they play significant roles in influencing the efficacy and bioavailability of pharmaceutical agents in humans. It is also known that multiple types of cancer tissue frequently have high levels of GSTs compared to the corresponding healthy tissue. Herein, firstly, the GST was purified from human erythrocytes by rapid and straightforward chromatographic techniques. Subsequently, the active infection medications, the antimycotics (amphotericin B, anidulafungin, and caspofungin), antibacterials (daptomycin, ertapenem, and tigecycline), and antiviral (ganciclovir) were assessed for their inhibitory actions versus GST. All drugs demonstrated micromolar levels of potent inhibitory activity towards GST. Antifungal drugs had KI constants ranging between 20.60±0.05 μM and 50.43±0.12 μM, whilst antibacterial drugs exhibited KIs in the range of 20.92±0.09–114.80±0.41 μM. Daptomycin and ertapenem exhibited competitive inhibition, while other drugs in noncompetitive inhibition. Moreover, amphotericin B exhibited the most potent inhibitory activity (KI=20.60±0.05 μM), and in contrast, antiviral drug ganciclovir had the highest inhibition constant (KI=463.10±1.28 μM). Studying both in-vitro inhibitory activity and molecular docking interactions in silico activities of these infection medications in complex with the GST, an enzyme biologically important, demonstrates was caused significant associations between these drugs and GST were detected. The results here might provide structural guidance to design more potent GST inhibitors. © 2021 Wiley-VCH GmbH
dc.description.sponsorship. This work was supported by the Research Fund of Anadolu University (grant number 2102S003)
dc.identifier.doi10.1002/slct.202103197
dc.identifier.endpage11924
dc.identifier.issn2365-6549
dc.identifier.issue43
dc.identifier.scopus2-s2.0-85119579134
dc.identifier.startpage11915
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/13372
dc.identifier.volume6
dc.identifier.wosWOS:000720942400009
dc.language.isoen
dc.publisherJohn Wiley and Sons Inc
dc.relation.ispartofChemistrySelect
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAntibacterial Drugs
dc.subjectAntifungal Drugs
dc.subjectBiological Activity
dc.subjectEnzymes
dc.subjectGlutathione S-Transferase
dc.subjectInhibition
dc.titleInfection Medications: Assessment In-Vitro Glutathione S-Transferase Inhibition and Molecular Docking Study
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus54
rdl.citation.wos53
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)